array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Tekla Life Sciences Investors" ["slug"]=> string(38) "30be8-us-tekla-life-sciences-investors" ["logo"]=> NULL ["description"]=> string(523) "Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL." ["address_street"]=> string(17) "2 Liberty Sq FL 9" ["address_place"]=> string(6) "Boston" ["address_region"]=> string(13) "Massachusetts" ["founding_date"]=> string(10) "2000-01-26" ["website_domain"]=> string(12) "teklacap.com" ["website_url"]=> string(24) "https://www.teklacap.com" ["industry_codes"]=> array(1) { [0]=> string(39) "Management Investment Offices, Open-End" } ["employee_count"]=> int(7) ["article_count"]=> int(78) } ["articles"]=> array(1) { [0]=> array(7) { ["title_en"]=> string(84) "Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Graham Capital Management L.P." ["snippet_en"]=> string(296) "Graham Capital Management L.P. raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 108.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,569 shares of the company's stock after acquiring a" ["url"]=> string(73) "https://www.marketbeat.com/instant-alerts/nyse-jnj-sec-filing-2023-11-30/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3002266e-8d28-47bf-a243-7dc9f574377a" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-11-30" ["categories"]=> array(8) { [0]=> string(11) "Acquisition" [1]=> string(20) "Corporate Governance" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(12) "Stock Market" [5]=> string(16) "Share Repurchase" [6]=> string(18) "General Investment" [7]=> string(14) "Issuing Shares" } } } ["category_annotations"]=> array(22) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(16) } [1]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(6) } [2]=> array(2) { ["name"]=> string(10) "Tax Havens" ["count"]=> int(6) } [3]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(5) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(4) } [5]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(4) } [6]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(4) } [7]=> array(2) { ["name"]=> string(16) "Share Repurchase" ["count"]=> int(4) } [8]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(3) } [9]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [11]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(2) } [12]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [13]=> array(2) { ["name"]=> string(22) "Business Restructuring" ["count"]=> int(2) } [14]=> array(2) { ["name"]=> string(20) "Corporate Governance" ["count"]=> int(2) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(23) "Supply Chain Management" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(19) "Investment Requests" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(1) } } } 30be8-us-tekla-life-sciences-investors